Invivyd, Inc.
NASDAQ:IVVDBiotechnology
Healthcare
$0.47 +4.16%
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
52W Low $0.48High $3.07
Volume 6.71M
Average 3.62M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$58.13M
FY 2025 · Annual
Investing Cash Flow
-$155,000.00
FY 2025 · Annual
Financing Cash Flow
$215.63M
FY 2025 · Annual
+448.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.76M | 21.65M | 18.69M | 19.79M | 11.64M |
| Change in Working Capital | 22.79M | (16.13M) | 5.89M | (23.47M) | (19.69M) |
| Accounts Receivables | 0 | 0 | 0 | (10.91M) | (3.34M) |
| Inventory | 0 | 0 | 0 | (24.89M) | (373K) |
| Accounts Payables | (2.37M) | (4.3M) | 6.47M | 2.42M | 3.21M |
| Other Working Capital | 25.16M | (11.83M) | (583K) | 9.91M | (19.2M) |
| Other Non-Cash Items | 1.5M | 15.35M | (1.12M) | 19.79M | 298K |
| Operating Cash Flow | (184.74M) | (219.99M) | (173.16M) | (170.49M) | (58.14M) |
| Capital Expenditures | (84K) | (1.71M) | (615K) | (140K) | (155K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.63M) | (297.96M) | (91.2M) | 0 | 0 |
| Sales of Investments | 138M | 69M | 372.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71M) | (230.67M) | 280.68M | (140K) | (155K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 330.91M | 510K | 1.2M | 39.29M | 215.63M |
| Common Stock Repurchased | 0 | (4K) | (1K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.39M) | 510K | 1.05M | 46K | 0 |
| Financing Cash Flow | 662.68M | 506K | 1.05M | 39.33M | 215.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 8K | 0 |
| Net Change in Cash | 427.24M | (450.15M) | 108.57M | (131.29M) | 157.34M |
| Free Cash Flow | (184.82M) | (221.69M) | (173.78M) | (170.63M) | (58.29M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$52.5M
+ D&A$2.1M
+ Stock-Based Comp$11.6M
+ Deferred Tax$0
- Working Capital-$19.7M
+ Other Non-Cash$298.0K
= Operating Cash Flow-$58.1M
- Capex-$155.0K
= Free Cash Flow-$58.3M
Analysis
FY2025 free cash flow is -$58.3M. FCF conversion is 111.1% of net income. Operating cash flow was -$58.1M, with capex of -$155.0K. The largest bridge item is Working Capital at -$19.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 29, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 1, 2026 | |
| 8-K | Current report | Sep 1, 2026 |
Does IVVD generate free cash flow?
Invivyd, Inc. (IVVD) generated -$58.29M of free cash flow in fiscal 2025.
How much operating cash flow does IVVD produce?
Operating cash flow was -$58.13M, before capital expenditures of $155,000.00.
Continue the stock analysis
Jump to another research area for this company.